228 related articles for article (PubMed ID: 25150193)
21. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.
Reinisch W; Gottlieb K; Colombel JF; Danese S; Panaccione R; Panes J; Peyrin-Biroulet L; Rubin D; Sands BE; Schreiber S; Vermeire S; Mulberg A; Sandborn B
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1673-1679.e1. PubMed ID: 31352970
[TBL] [Abstract][Full Text] [Related]
22. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
[TBL] [Abstract][Full Text] [Related]
23. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.
Polak TB; van Rosmalen J; Uyl-de Groot CA
Br J Clin Pharmacol; 2020 Sep; 86(9):1819-1826. PubMed ID: 32200551
[TBL] [Abstract][Full Text] [Related]
24. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A
Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165
[TBL] [Abstract][Full Text] [Related]
25. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
Seo Y; Pacifici E
Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
[TBL] [Abstract][Full Text] [Related]
26. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
27. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
[TBL] [Abstract][Full Text] [Related]
28. A Comparison of FDA and EMA Pregnancy and Lactation Labeling.
Kappel D; Sahin L; Yao L; Thor S; Kweder S
Clin Pharmacol Ther; 2023 Jun; 113(6):1251-1257. PubMed ID: 36645246
[TBL] [Abstract][Full Text] [Related]
29. A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling.
de Jong LM; Klomp SD; Treijtel N; Rissmann R; Swen JJ; Manson ML
Br J Clin Pharmacol; 2022 Oct; 88(10):4387-4402. PubMed ID: 35484780
[TBL] [Abstract][Full Text] [Related]
30. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
[TBL] [Abstract][Full Text] [Related]
31. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
Erhel F; Scanff A; Naudet F
Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
[TBL] [Abstract][Full Text] [Related]
32. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views.
Tafuri G; Stolk P; Trotta F; Putzeist M; Leufkens HG; Laing RO; De Allegri M
Ann Oncol; 2014 Jan; 25(1):265-9. PubMed ID: 24356637
[TBL] [Abstract][Full Text] [Related]
33. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports.
Chang L; Dhruva SS; Chu J; Bero LA; Redberg RF
BMJ; 2015 Jun; 350():h2613. PubMed ID: 26063311
[TBL] [Abstract][Full Text] [Related]
34. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
[TBL] [Abstract][Full Text] [Related]
35. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference.
Yu LX; Baker J; Berlam SC; Boam A; Brandreth EJ; Buhse L; Cosgrove T; Doleski D; Ensor L; Famulare J; Ganapathy M; Grampp G; Hussong D; Iser R; Johnston G; Kesisoglou F; Khan M; Kozlowski S; Lacana E; Lee SL; Miller S; Miksinski SP; Moore CM; Mullin T; Raju GK; Raw A; Rosencrance S; Rosolowsky M; Stinavage P; Thomas H; Wesdyk R; Windisch J; Vaithiyalingam S
AAPS J; 2015 Jul; 17(4):1011-8. PubMed ID: 25840884
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted.
Pradhan S; Wright DFB; Duffull SB
Br J Clin Pharmacol; 2021 Mar; 87(3):1401-1410. PubMed ID: 32857419
[TBL] [Abstract][Full Text] [Related]
38. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
39. Advancing structured decision-making in drug regulation at the FDA and EMA.
Angelis A; Phillips LD
Br J Clin Pharmacol; 2021 Feb; 87(2):395-405. PubMed ID: 32529733
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Drug Approvals in Europe Versus the United States: An Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA.
Makuch RW; Shi R
Ther Innov Regul Sci; 2014 May; 48(3):362-366. PubMed ID: 30235531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
